Harmony Biosciences Holdings, Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Harmony Biosciences (market cap ~$1.3B) reported Q2 2026 WAKIX net revenue of $261.3 million, up 30% YoY, with 8,950 average patients (+450 net adds). The company reiterates full-year 2026 guidance of $1.0–$1.04 billion. Separately, BP-205 Phase 1 SAD data showed favorable pharmacokinetics (Tmax 30–75 min, T½ ~25h supporting once-daily dosing) and safety; the company plans Phase 1b in Q3, Phase 2 in mid-2027. Cash position strengthened to $962.5M (from $882.5M at year-end 2025).
Why this rating
Record revenue quarter and FY guidance reaffirm core business strength; BP-205 data encouraging but early-stage. Pipeline catalysts 2027–2028 matter, but execution risk remains high. Balanced by $962.5M cash enabling strategic M&A.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.